Dashboard
Manage Tickers

VERU VERU INC.

Nasdaq verupharma.com


$ 2.91 $ -0.03 (-1.02 %)    

Friday, 31-Oct-2025 11:44:55 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 632.16 $ -1.83 (-0.29 %)
DIA $ 475.30 $ -0.62 (-0.13 %)
SPY $ 683.37 $ -1.70 (-0.25 %)
TLT $ 90.26 $ -0.29 (-0.32 %)
GLD $ 369.87 $ -0.64 (-0.17 %)
$ 3.01
$ 2.95
$ 2.89 x 1,010
$ 2.92 x 700
$ 2.88 - $ 2.97
$ 2.64 - $ 14.20
765,754
na
44.1M
$ 0.12
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 02-13-2025 12-31-2024 10-Q
4 12-16-2024 09-30-2024 10-K
5 08-08-2024 06-30-2024 10-Q
6 05-08-2024 03-31-2024 10-Q
7 04-01-2024 12-31-2023 10-Q
8 12-08-2023 09-30-2023 10-K
9 08-10-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 02-09-2023 12-31-2022 10-Q
12 12-05-2022 09-30-2022 10-K
13 08-11-2022 06-30-2022 10-Q
14 05-12-2022 03-31-2022 10-Q
15 02-09-2022 12-31-2021 10-Q
16 12-02-2021 09-30-2021 10-K
17 08-12-2021 06-30-2021 10-Q
18 05-12-2021 03-31-2021 10-Q
19 02-10-2021 12-31-2020 10-Q
20 12-10-2020 09-30-2020 10-K
21 08-13-2020 06-30-2020 10-Q
22 05-13-2020 03-31-2020 10-Q
23 02-12-2020 12-31-2019 10-Q
24 12-12-2019 09-30-2019 10-K
25 08-08-2019 06-30-2019 10-Q
26 05-15-2019 03-31-2019 10-Q
27 02-13-2019 12-31-2018 10-Q
28 12-13-2018 09-30-2018 10-K
29 08-14-2018 06-30-2018 10-Q
30 05-11-2018 03-31-2018 10-Q
31 02-14-2018 12-31-2017 10-Q
32 01-02-2018 09-30-2017 10-K
33 08-09-2017 06-30-2017 10-Q
34 05-10-2017 03-31-2017 10-Q
35 02-09-2017 12-31-2016 10-Q
36 12-12-2016 09-30-2016 10-K
37 07-28-2016 06-30-2016 10-Q
38 04-28-2016 03-31-2016 10-Q
39 02-02-2016 12-31-2015 10-Q
40 12-02-2015 09-30-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

veru-to-present-enobosarm-data-at-obesityweek-2025-highlighting-lean-mass-preservation-and-fat-loss-selectivity
Veru to Present Enobosarm Data At ObesityW...
10/31/2025 12:44:07

Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the tre...

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
10/30/2025 17:07:10

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
10/30/2025 12:08:54

veru-announces-pricing-of-25m-public-offering-of-14m-shares-of-common-stock-at-a-price-of-300-per-unit
Veru Announces Pricing Of $25M Public Offe...
10/30/2025 12:08:08

Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the tre...

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
10/29/2025 21:06:30

veru-reveals-proposed-public-offering-no-size-disclosed
Veru Reveals Proposed Public Offering; No ...
10/29/2025 20:02:28

Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the tre...

eli-lilly-ends-bimagrumab-obesity-study-weeks-after-launch
Eli Lilly Ends Bimagrumab Obesity Study We...
09/25/2025 15:23:56

On Wednesday, Eli Lilly & Co. (NYSE: LLY) ended a mid-stage study of its experimental drug bimagrumab in obesity patients w...

veru-secures-fda-regulatory-clarity-for-enobosarm-to-enhance-weight-loss-with-glp-1-ra-plans-phase-2b-plateau-study-in-obesity-treatment
Veru Secures FDA Regulatory Clarity For En...
09/23/2025 12:36:43

Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the tre...

raymond-james-maintains-outperform-on-veru-lowers-price-target-to-20
Raymond James Maintains Outperform on Veru...
08/13/2025 12:49:42

Raymond James analyst Gary Nachman maintains Veru (NASDAQ:VERU) with a Outperform and lowers the price target from $30 to $20.

veru-q3-eps-050-versus-071-prior-year
Veru Q3 EPS $(0.50) Versus $(0.71) Prior Year
08/12/2025 10:32:35

Core News & Articles
Earnings Scheduled For August 12, 2025
08/12/2025 08:32:28

veru-selected-modified-release-oral-formulation-of-enobosarm-utilizing-laxxons-proprietary-spid-technology
Veru Selected Modified-Release Oral Formul...
08/11/2025 20:16:00

a-look-ahead-verus-earnings-forecast
A Look Ahead: Veru's Earnings Forecast
08/11/2025 18:03:59

trading-halt-halt-status-updated-at-85500-am-et-quotation-resumption-news-and-resumption-times
Trading Halt: Halt status updated at 8:55:...
08/11/2025 12:55:04

veru-announces-1-for-10-reverse-stock-split
Veru Announces 1-For-10 Reverse Stock Split
08/06/2025 12:31:22

veru-reports-topline-efficacy-and-safety-results-from-maintenance-extension-portion-of-phase-2b-quality-study-demonstrating-that-in-12-weeks-after-stopping-semaglutide-placebo-monotherapy-group-regained-43-of-body-weight-while-enobosarm-monotherapy-reduced-weight-regain-by-46
Veru Reports Topline Efficacy And Safety R...
06/24/2025 12:33:14

--During the Maintenance Period of 12 weeks after discontinuing semaglutide (GLP-1 receptor agonist), placebo group regained 43...

verus-enobosarm-shows-muscle-in-wegovy-combo-trial
Veru's Enobosarm Shows Muscle In Wegovy Co...
05/28/2025 16:11:21

Veru reports strong safety and efficacy for enobosarm added to semaglutide, showing reduced functional decline and muscle loss ...

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
05/28/2025 12:08:42

veru-announced-topline-safety-results-from-phase-2b-quality-study-of-enobosarm-3mg-enobosarm-6mg-or-placebo-to-enhance-fat-loss-and-to-prevent-muscle-loss-in-older-patients-receiving-semaglutide-wegovy-for-chronic-weight-management
Veru Announced Topline Safety Results From...
05/28/2025 10:33:35

Enobosarm 3mg added to semaglutide resulted in the highly selective loss of fat mass, accounting for 99% of the total weight lo...

veru-q2-eps-005-beats-006-estimate
Veru Q2 EPS $(0.05) Beats $(0.06) Estimate
05/08/2025 10:32:40

Veru (NASDAQ:VERU) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.06) by 16.67...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION